SIONNA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | — | $60.3M | $57.3M |
| SG&A Expense | — | $28.7M | $13.3M |
| Operating Income | — | $-89.0M | $-70.6M |
| Operating Margin | — | — | — |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | — | $0 | $0 |
| Net Income | — | $-75.3M | $-61.7M |
| Net Margin | — | — | — |
| EPS (Basic) | — | $-1.88 | $-1.60 |
| EPS (Diluted) | — | $-1.88 | $-1.60 |
| Shares Outstanding (Basic) | 45.0M | 40.0M | 38.6M |
| Shares Outstanding (Diluted) | 45.0M | 40.0M | 38.6M |
| Dividends Per Share | — | — | — |